Martin C Runnstrom
Overview
Explore the profile of Martin C Runnstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lamothe P, Pruett C, Smirnova N, Shepherd A, Runnstrom M, Park J, et al.
J Allergy Clin Immunol Glob
. 2024 Dec;
4(1):100369.
PMID: 39736892
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a disease resulting from an overactive type 2 response to . Initial studies suggest that asthma biologics can effectively treat ABPA, but it is...
2.
Faliti C, Van T, Anam F, Cheedarla N, Williams M, Mishra A, et al.
Nat Immunol
. 2024 Dec;
26(1):148.
PMID: 39622950
No abstract available.
3.
Faliti C, Van T, Anam F, Cheedarla N, Williams M, Mishra A, et al.
Nat Immunol
. 2024 Nov;
26(1):131-145.
PMID: 39533072
Severe acute respiratory syndrome coronavirus 2 mRNA vaccination has reduced effectiveness in certain immunocompromised individuals. However, the cellular mechanisms underlying these defects, as well as the contribution of disease-induced cellular...
4.
Lamothe P, Runnstrom M, Lee F
J Allergy Clin Immunol
. 2024 Nov;
155(1):238-239.
PMID: 39520412
No abstract available.
5.
Nguyen D, Hentenaar I, Morrison-Porter A, Solano D, Haddad N, Castrillon C, et al.
Nat Med
. 2024 Sep;
31(1):235-244.
PMID: 39333316
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are effective at protecting from severe disease, but the protective antibodies wane rapidly even though SARS-CoV-2-specific plasma cells can be found...
6.
Haddad N, Morrison-Porter A, Quehl H, Capric V, Lamothe P, Anam F, et al.
medRxiv
. 2024 Jul;
PMID: 39006446
Post-acute sequelae of SARS-CoV-2 (SARS2) infection (PASC) is a heterogeneous condition, but the main viral drivers are unknown. Here, we use MENSA, Media Enriched with Newly Synthesized Antibodies, secreted exclusively...
7.
Runnstrom M, Lamothe P, Faliti C, Cheedarla N, Moreno A, Suthar M, et al.
J Allergy Clin Immunol
. 2024 Jun;
154(2):435-446.
PMID: 38878020
Background: Biologic therapies inhibiting the IL-4 or IL-5 pathways are very effective in the treatment of asthma and other related conditions. However, the cytokines IL-4 and IL-5 also play a...
8.
Faliti C, Anam F, Cheedarla N, Woodruff M, Usman S, Runnstrom M, et al.
medRxiv
. 2023 Jul;
PMID: 37398319
Novel mRNA vaccines have resulted in a reduced number of SARS-CoV-2 infections and hospitalizations. Yet, there is a paucity of studies regarding their effectiveness on immunocompromised autoimmune subjects. In this...
9.
Woodruff M, Ramonell R, Haddad N, Anam F, Rudolph M, Walker T, et al.
Nature
. 2022 Aug;
611(7934):139-147.
PMID: 36044993
Severe SARS-CoV-2 infection has been associated with highly inflammatory immune activation since the earliest days of the COVID-19 pandemic. More recently, these responses have been associated with the emergence of...
10.
Runnstrom M, Lee F
Am J Respir Crit Care Med
. 2022 May;
206(5):647-648.
PMID: 35612925
No abstract available.